Samlyn Capital’s Novartis NVS Stock Holding History

Samlyn Capital’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-432,678	Closed	-$39.5M	–	135
2019 Q2	$39.5M	Buy	+432,678	New	+$36.6M	0.83%	46
2018 Q1	–	Sell	-257,024	Closed	-$19.3M	–	148
2017 Q4	$19.3M	Buy	257,024 +13,339	+5%	+$1.01M	0.44%	76
2017 Q3	$18.7M	Sell	243,685 -11,991	-5%	-$906K	0.47%	68
2017 Q2	$19.1M	Sell	255,676 -118,965	-32%	-$8.43M	0.47%	64
2017 Q1	$24.9M	Buy	+374,641	New	+$25M	0.58%	64

Other funds holding NVS

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Mawer Investment Management Calgary, Alberta, Canada $14.7B AUM 12.5% 1-Year Est. Return

Samlyn Capital's NVS Position: Q3 2019 in Review

Samlyn Capital sold out of Novartis (NVS) in Q3 2019, closing a stake of 432,678 shares — an estimated $39.5M sold.

Samlyn Capital first reported a position in NVS in Q1 2017 and held it in 5 quarters. The position peaked at $39.5M in Q2 2019. 1,091 funds tracked by Wall St. Rank hold NVS as of Q3 2019.

Samlyn Capital reported no remaining Novartis position as of Q3 2019 after selling out during the quarter.
Samlyn Capital sold 432,678 Novartis shares in Q3 2019, an estimated $39.5M.
Samlyn Capital first reported a position in Novartis in Q1 2017 and held it in 5 quarters.
Samlyn Capital's Novartis position peaked at $39.5M in Q2 2019.
1,091 funds tracked by Wall St. Rank held Novartis as of Q3 2019.

Based on Samlyn Capital's 13F filing for Q3 2019, filed 14 Nov 2019.